VALIDOGEN presenting advanced protein production tools at RPP conference in Crete
PRESS RELEASE | VALIDOGEN GmbH
APRIL 10, 2019
Grambach, Austria: Protein expression specialist VALIDOGEN will be a prominent presence as sponsor and presenter at the recombinant protein production (RPP) 2019 conference on the Greek island of Crete.
VALIDOGEN, formerly VTU Technology, will be presenting advantages of its ‘UNLOCK PICHIA’ toolbox as a competitive element in advanced recombinant protein production.
Dr. Roland Weis, VALIDOGEN’s Head of Operations, will contribute to the ‘Recombinant protein production processes at industrial scale’ session on Day Three (11.20-11.40 hrs, April 26) with his presentation on ‘Productivity through diversity – a protein production toolbox to UNLOCK PICHIA’.
“Novel product classes and current trends in biopharma production ask for versatile and yet robust expression systems. Our answer is a yield-enhancing protein production toolbox, ‘UNLOCK PICHIA’, that enables fine-tuning of protein expression by its diversity of molecular tools and expression strategies for Pichia,” Dr. Weis explained.
AOX-1 promoter library
His presentation will show how VALIDOGEN’s Pichia toolbox including an exclusive AOX1-promoter library (with and without methanol induction) leverages gene/protein-customized expression which translates into high-level production strains already identified from high-throughput cultivation and screening in microscale format.
Due to this robust deep-well plate cultivation method, rapid and most importantly reliable transfer to bioreactors and further scale-up is ensured, which is manifested by production campaigns in up to 100,000L scale with a strain as well as a cultivation process developed with VALIDOGEN.
Clearing expression bottlenecks
Continuous expansion and improvement of its technology platform facilitates the targeted debottlenecking of protein expression all the way from transcription and translation to translocation, protein folding and secretion, thereby facilitating the expression of more complex proteins without compromising product quality.
Dr. Weis will share results from showcase productions as well as dedicated industrial projects, spanning the fields of biopharma and diagnostic products over industrial enzymes and enzyme engineering via directed evolution.
About VALIDOGEN GmbH
VALIDOGEN GmbH (previously VTU Technology), a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression and production.
VALIDOGEN´s yield-enhancing UNLOCK PICHIA expression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening and cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance. The platform enables highest productivities delivering up to 25 g/L of secreted protein (record productivities of 35 g/L) within a few weeks development time.
VALIDOGEN develops high performance expression strains and economically viable protein production processes for the manufacture of biopharmaceuticals, enzymes and various other recombinant proteins and provides tailor- made solutions for customers from different industry sectors – such as pharma, diagnostics, food & feed, chemical, agro and other industries.
Headquartered in Grambach, near Graz, Austria, VALIDOGEN is a private company.
About RPP 2019
The RPP conference is a biennial event that offers a comprehensive overview of current challenges and innovative solutions in recombinant protein production, focusing on the comparative physiology of microbial and higher eukaryotic platforms for protein production.
The 2019 RPP conference (RPP10) is a four-day event opening April 24 at the Creta Maris Hotel at Hersonissos near Heraklion, Crete.
The conference will build on the successes of previous meetings, which have attracted steadily increasing numbers of researchers from both academia and the bioprocessing industry. The meeting will address major areas and emerging trends in industrially relevant recombinant protein production, including host physiology under bioprocess conditions, cell engineering, industrial-scale processes and new-format or difficult to express proteins.
The event is jointly organized by the European Federation of Biotechnology (EFB) Microbial Physiology Section in partnership with the Federation of European Microbiological Societies (FEMS). Further information at: http://www.efbiotechnology.org/RPP.
Dr. Thomas Purkarthofer, Head of Business Development, VALIDOGEN GmbH
Tel.: +43 316 4009 4017